Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes

European Journal of Clinical Nutrition

Volumn 62, Issue 3, 2008, Pages 419-429

  Mostad, Ingrid L ^a,b   Bjerve, K S ^b   Lydersen, S ^c   Grill, V ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CORN OIL; FISH OIL; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEGA 3 FATTY ACID; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; EATING HABIT; FEMALE; FOOD INTAKE; GLUCOSE UTILIZATION; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARTICLE SIZE;

ZEA MAYS;

EID: 40549092344     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602703     Document Type: Article

References (41)

1. Baumstark MW, Frey I, Berg A, Keul J (1992). Influence of n-3 fatty acids from fish oils on concentration of high- and low-density lipoprotein subfractions and their lipid and apolipoprotein composition. Clin Biochem 25, 338-340.
2. Connor WE (2000). Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 71, 171S-175S.
3. Davis TM, Wright AD, Mehta ZM, Cull CA, Stratton IM, Bottazzo GF et al. (2005). Islet autoantibodies in clinically diagnosed type 2 diabetes: Prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48, 695-702.
4. Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE et al. (2005). Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111, 3465-3472.
5. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA (1998). Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 18, 1046-1053.
6. Friedewald WT, Levy RI, Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499-502.
7. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A et al. (2003). Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52, 453-462.
8. Goff Jr DC, D'Agostino Jr RB, Haffner SM, Otvos JD (2005). Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 54, 264-270.
9. Harris WS (1997). n-3 fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr 65, 1645S-1654S.
10. Harris WS (2004). Fish oil supplementation: Evidence for health benefits. Cleve Clin J Med 71, 208.
11. Harris WS, Connor WE, McMurry MP (1983). The comparative reductions of the plasma lipids and lipoproteins by dietary polyunsaturated fats: salmon oil versus vegetable oils. Metabolism 32, 179-184.
12. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R et al. (2001). Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21, 844-848.
13. Holvoet P, Vanhaecke J, Janssens S, Van de WF, Collen D (1998). Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98 1487-1494.
14. Jensen CV (1991). A computer program for randomizing patients with near-even distribution of important parameters. Comput Biomed Res 24, 429-434.
15. Julius U (2003). Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia. Exp Clin Endocrinol Diabetes 111, 246-250.
16. Luo J, Rizkalla SW, Vidal H, Oppert JM, Colas C, Boussairi A et al. (1998). Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 21, 717-724.
17. Malasanos TH, Stacpoole PW (1991). Biological effects of omega-3 fatty acids in diabetes mellitus. Diabetes Care 14, 1160-1179.
18. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W (2005). Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112, 651-657.
19. Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC et al. (2000). ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 20, 1990-1997.
20. Montori VM, Farmer A, Wollan PC, Dinneen SF (2000). Fish oil supplementation in type 2 diabetes: A quantitative systematic review. Diabetes Care 23, 1407-1415.
21. Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ (1999). Dietary fish as a major component of a weight-loss diet: Effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr 70 (5), 817-825.
22. Mostad IL, Bjerve KS, Bjørgaas MR, Lydersen S, Grill V (2006). Effects of n-3 fatty acids in subjects with type 2 diabetes: Reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr 84, 540-550.
23. Nestel PJ (2000). Fish oil and cardiovascular disease: Lipids and arterial function. Am J Clin Nutr 71, 228S-231S.
24. Otvos JD (2002). Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48, 171-180.
25. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM (1992). Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 38, 1632-1638.
26. Packard CJ (2006). Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 17, 412-417.
27. Patti L, Maffettone A, Iovine C, Marino LD, Annuzzi G, Riccardi G et al. (1999). Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 146, 361-367.
28. Petersen M, Dyrby M, Toubro S, Engelsen SB, Norgaard L, Pedersen HT et al. (2005). Quantification of lipoprotein subclasses by proton nuclear magnetic resonance-based partial least-squares regression models. Clin Chem 51, 1457-1461.
29. Petersen M, Pedersen H, Major-Pedersen A, Jensen T, Marckmann P (2002). Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 25, 1704-1708.
30. Pocock SJ, Simon R (1975). Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31, 103-115.
31. Rimestad AH, Blaker B, Flåten A-M, Nordbotten A (1995). Den store matvaretabellen (The Norwegian Food Table). In norwegian. Universitetsforlaget: Oslo.
32. Scheffer PG, Bos G, Volwater HG, Dekker JM, Heine RJ, Teerlink T (2003). Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in type 2 diabetic patients. Diabet Med 20, 563-567.
33. Steinmetz A (2003). Treatment of diabetic dyslipoproteinemia. Exp Clin Endocrinol Diabetes 111, 239-245.
34. Sullivan DR, Sanders TA, Trayner IM, Thompson GR (1986). Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis 61, 129-134.
35. Suzukawa M, Abbey M, Howe PR, Nestel PJ (1995). Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 36, 473-484.
36. Syvänne M, Taskinen MR (1997). Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 350 (Suppl 1), SI20-SI23.
37. Vickers AJ, Altman DG (2001). Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 323, 1123-1124.
38. Wilkinson P, Leach C, Ah-Sing EE, Hussain N, Miller GJ, Millward DJ et al. (2005). Influence of alpha-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 181, 115-124.
39. Witte DR, Taskinen MR, Perttunen-Nio H, Van TA, Livingstone S, Colhoun HM (2004). Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J Lipid Res 45, 1069-1076.
40. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ (2002). Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 76, 1007-1015.
41. Yu HH, Ginsburg GS, O'Toole ML, Otvos JD, Douglas PS, Rifai N (1999). Acute changes in serum lipids and lipoprotein subclasses in triathletes as assessed by proton nuclear magnetic resonance spectroscopy. Arterioscler Thromb Vasc Biol 19, 1945-1949.